Will doctors one day prescribe apps meant to drive behavior changes instead of drugs?

The reSET-O app uses cognitive behavioral therapy techniques to assist patients engaged in medication-assisted therapy for opioid dependence.

Five-to-ten times stronger than fentanyl, this drug is not for consumer use, and many claim it could worsen the opioid crisis.

Cassipa (buprenorphine and naloxone) sublingual film delivers a new dosage for the treatment of opioid dependence.

The FDA is working to create new opioid prescribing practices and guidelines, while also shifting drug development priorities for pain medications.

Healthesystems’ Chief Medical Officer spoke with WorkCompCentral regarding DEA plans to reduce opioid manufacturing.

Drugs to treat opioid dependence could be approved under new clinical endpoints other than reducing opioid use.

The FDA recently approved drugs to treat opioid dependence, migraines, and rheumatoid arthritis.

A newly released draft guidance encourages the development of more sustained-release buprenorphine products.

Kratom continues to grow in popularity as a drug for pain and opioid withdrawal, despite concerns from the FDA, CDC and DEA.